For the families who have turned to peptide injections, and for the doctors who treat them, the rules just changed. On Wednesday the Trump administration moved to ease access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. The Associated Press reported that scientific staffers at the Food and Drug Administration had little input and opposed the changes, according to six people familiar with how the policy was developed.
What the policy does
The Department of Health and Human Services directed the FDA not to act against specialty pharmacies that sell six wellness peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Under FDA rules these chemicals would otherwise count as illegal drugs, because none has been through the agency’s review for safety and effectiveness. The document is titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” The government will take comments for two weeks, and final publication is set for October 30.
The policy does not change the peptides’ regulatory status. It only says HHS will stop enforcement against compounding pharmacies that make them.
HHS originally wanted the FDA to write a formal regulation adding BPC-157 and other peptides to a list of substances deemed safe for compounding pharmacies. FDA officials warned that their scientists had serious safety concerns and would not back such a rule, so HHS switched to enforcement discretion. FDA staff then helped with technical guardrails, including peptide ingredients from FDA-registered factories, collection of side-effect reports and purity checks. Peter Lurie pointed out that under federal law the FDA cannot enforce those pharmacy requirements.
Why Kennedy says it matters
Kennedy has called himself a “big fan” of peptides and has said he used BPC-157 for a muscle injury. According to the posted document, he concluded the change “advances patient choice and freedom” while shielding Americans from peptides sold online that are often made from unscreened ingredients. HHS spokesperson Emily Hilliard said the policy requires “patient-specific prescriptions, traceable ingredients, quality testing and safety reporting to hold compounders accountable and give patients an alternative to unregulated sellers.”
That alternative has a real constituency. Many peptide users today skip doctors and pharmacies and order vials online from chemical makers in China, often labeled “for research use only” to sidestep FDA oversight. In 2023 the FDA put more than a dozen peptides, BPC-157 and TB-500 among them, on its list of substances that should not be compounded because of risks of allergic reactions, kidney damage and tumor growth.
Some peptides do occur naturally in the body, where they trigger hormones that drive growth, metabolism and healing, and drug companies have turned several into medicines, including mainstay diabetes and weight-loss treatments. Lee Rosebush of the American Academy of Peptide Medicine called the move “a huge step for patient and provider medical freedom.” His group is not a medical professional organization; it represents people who prescribe or sell peptides.
Doctors and pharmacists react
Wall Street analysts put the market at more than $2 billion, and telehealth companies including Hims & Hers have announced plans to offer wellness peptides once the policy changed. Dr. Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest, noted that the peptides are promoted for insomnia, anxiety, inflammatory conditions and migraines, and that the FDA has already approved rigorously tested drugs for all of them. As people “are diverted from those drugs toward this stuff, there will be more unnecessary pain and suffering,” he said. He also questioned the timing, days before the midterm election.
Dr. Robert Steinbrook of Public Citizen said Kennedy had “undermined the FDA and threatened public health,” and that all peptide substances should go through the standard approval process for new drugs. Willie Underwood III, president of the American Medical Association, said the peptides have “not undergone the rigorous testing required of FDA-approved drugs.” Shabbir Safda of the Partnership for Safe Medicines said the decision leaves Americans in a “grey area as to whether peptides are safe or not.”
Pharmacies are split on how fast they can respond. Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, said “We won’t be able to meet demand.” His company needs time to ready its facility and will likely compound only one of the six. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said his group welcomes a “more accountable alternative” for patients now buying on the gray market, though the alliance also wants clarity on when the policy takes effect and how it fits with state pharmacy boards.
What this means for patients
HHS itself says “compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.” It calls the drugs “experimental” and describes the action as meant to “expand and improve patient access while FDA reviews these substances.” In plain terms, anyone who takes them is still taking them at their own risk.
Anyone weighing a peptide for an injury, for energy or for a chronic condition should talk it through with a qualified doctor or pharmacist first, and with an oncologist if cancer is part of the picture.
Sources
- RFK Jr. acts to ease access to unproven peptides despite opposition from FDA scientists | CNN
- RFK Jr Opens the Floodgates on Experimental Peptides, Alarming Scientists
- HHS Orders FDA To Stop Enforcement Against Pharmacies Selling Six Unproven Peptides: how 7 outlets framed it | NewsCord
Photo: U.S. Department of Health and Human Services (Public domain)





